Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ...
Taiwan News

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in ...
Kalkine Media

Tiziana Brain Trial Draws Fresh Nasdaq Index Attention

Tiziana Life Sciences reported encouraging brain inflammation findings in its MSA study, strengthening attention on ...

Alterity strengthens ATH434 case with validated brain imaging biomarker in MSA

Publication of a peer-reviewed study from Alterity Therapeutic’s bioMUSE study shows an advanced MRI imaging method detects ...
MedPage Today on MSN

Is Pure Autonomic Failure a Warning Sign for Parkinson's? What a New Study Shows.

High conversion rates to Parkinson's, dementia with Lewy bodies, or multiple system atroph ...

Tiziana Life Sciences Ltd.: Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System AtrophyBOSTON, May 14 ...